Asunaprevir
|
|
|
- CAS-Nr.
- 630420-16-5
- Englisch Name:
- Asunaprevir
- Synonyma:
- CS-1413;BMS 650032;Asunaprevir;Asunaprevir API;Asunaprevir,≥98%;Asunaprevir 98.5%;Asunaprevir USP/EP/BP;BMS 650032/Asunaprevir;Asunaprevir (BMS-650032);Asunaprevir (10mM in DMSO)
- CBNumber:
- CB92614356
- Summenformel:
- C35H46ClN5O9S
- Molgewicht:
- 748.29
- MOL-Datei:
- 630420-16-5.mol
|
Asunaprevir Eigenschaften
- Schmelzpunkt:
- 149-150oC
- Dichte
- 1.37
- storage temp.
- -20°C Freezer, Under inert atmosphere
- L?slichkeit
- DMSO (Slightly), Methanol (Slightly, Heated)
- Aggregatzustand
- Solid
- pka
- 4.49±0.40(Predicted)
- Farbe
- White to Off-White
- InChIKey
- XRWSZZJLZRKHHD-QGQNBIQGSA-N
- SMILES
- CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| WGK Germany |
WGK 3 |
|
|
| Speicherklasse |
11 - Combustible Solids |
|
|
| Hazard Classifications |
STOT RE 2 |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
|
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
|
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Asunaprevir Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Sold under the trade name Sunvepra®, asunaprevir received
approval in Japan as part of a combination treatment for the hepatitis
C virus (HCV). Working in concert with daclatasvir (IX) (vide
infra), asunaprevir is a unique treatment for HCV, as it is free from both interferon and ribavirin and is administered orally. This
direct-acting anti-viral, which was developed by Bristol–Myers
Squibb (BMS), works as an NS3/4A protease inhibitor, representing
a valuable treatment option for patient populations who are
unable to receive, or do not respond to, the standard course of
treatment—peginterferon/ribavirin.
Enzyminhibitor
This highly selective HCV antiviral (FW = 748.29 g/mol; CAS 630420-16- 5; Symbol: ASV), also named BMS-650032, targets NS3 protease, a serine proteinase required for Hepatitis C Virus (HCV) polyprotein processing, showing good antiviral activity against replicons based on HCV Genotype 1a (EC50 = 4 nM), Genotype 1b (EC50 = 1.2 nM), Genotype 4 (EC50 = 1.8 nM), Genotype 5 (EC50 = 1.7 nM), and Genotype 6 (EC50 = 0.9 nM). It is far less effective against Genotype 2 (EC50 = 67 nM) and Genotype 3 (EC50 = >1100 nM). Asunaprevir is a peptidomimetic that occupies the active site, inhibiting the HCV NS3/4A serine protease, with little or no action against related viruses. The average Ki for ASV is approximately 0.4 nM and 0.2 nM for Genotype 1a and Genotype 1b, respectively. Its acylsulfonamide moeity interacts noncovalently with the NS3 protease – unlike telaprevir’s α-ketoamide moiety, which is linked covalently to NS3/4A’s catalytic serine and reverses slowly over time. ASV exhibits an excellent selectivity index (>40,000x) against all serine/cysteine proteases evaluated, including human leukocyte elastase, porcine pancreatic elastase, and three members of the chymotrypsin family. Although ASV shows a low barrier to resistance, it can be combined with daclatasvir to achieve a very high rate of viral eradication in both nave and treatment-experienced patients, showing a sustained virological response rate of 80%-90%.
Asunaprevir Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Asunaprevir Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 180)Lieferanten
- (1R,2S)-N-[(1,1-Dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenylcyclopropanecarboxamide
- Asunaprevir
- BMS 650032
- Asunaprevir (BMS-650032)
- BMS 650032/Asunaprevir
- Asunaprevir API
- tert-butyl N-[(2S)-1-[(2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
- BMS-650032; BMS 650032; BMS650032
- CS-1413
- tert-Butyl ((2S)-1-((2S)-2-(((1R,2S)-1-amino-2-vinylcyclopropane-1-carbonyl)(cyclopropylsulfonyl)carbamoyl)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate
- Asunaprevir,≥98%
- Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-, (1R,2S)-
- Asunaprevir USP/EP/BP
- Asunaprevir (10mM in DMSO)
- tert-Butyl ((S)-1-((2S,4R)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbama
- Asunaprevir 98.5%
- 630420-16-5
- C35H46ClN5O9S
- API
